Bill Text: FL S0530 | 2021 | Regular Session | Enrolled
Bill Title: Nonopioid Alternatives
Spectrum: Partisan Bill (Republican 1-0)
Status: (Passed) 2021-05-11 - Chapter No. 2021-12 [S0530 Detail]
Download: Florida-2021-S0530-Enrolled.html
ENROLLED 2021 Legislature SB 530, 2nd Engrossed 2021530er 1 2 An act relating to nonopioid alternatives; amending s. 3 456.44, F.S.; authorizing certain health care 4 practitioners to provide a specified educational 5 pamphlet to patients in an electronic format; 6 providing an effective date. 7 8 Be It Enacted by the Legislature of the State of Florida: 9 10 Section 1. Paragraph (c) of subsection (7) of section 11 456.44, Florida Statutes, is amended to read: 12 456.44 Controlled substance prescribing.— 13 (7) NONOPIOID ALTERNATIVES.— 14 (c) Except when a patient is receiving care in a hospital 15 critical care unit or emergency department or a patient is 16 receiving hospice services under s. 400.6095, before providing 17 care requiring the administration of anesthesia involving the 18 use of an opioid drug listed as a Schedule II controlled 19 substance in s. 893.03 or 21 U.S.C. s. 812, or prescribing or 20 ordering an opioid drug listed as a Schedule II controlled 21 substance in s. 893.03 or 21 U.S.C. s. 812 for the treatment of 22 pain, a health care practitioner who prescribes or orders an 23 opioid drug must: 24 1. Inform the patient or the patient’s representative of 25 available nonopioid alternatives for the treatment of pain, 26 which may include nonopioid medicinal drugs or drug products, 27 interventional procedures or treatments, acupuncture, 28 chiropractic treatments, massage therapy, physical therapy, 29 occupational therapy, or any other appropriate therapy as 30 determined by the health care practitioner. 31 2. Discuss with the patient or the patient’s representative 32 the advantages and disadvantages of the use of nonopioid 33 alternatives, including whether the patient is at a high risk 34 of, or has a history of, controlled substance abuse or misuse 35 and the patient’s personal preferences. 36 3. Provide the patient or the patient’s representative, 37 electronically or in printed form, witha printed copy ofthe 38 educational pamphlet described in paragraph (b). 39 4. Document the nonopioid alternatives considered in the 40 patient’s record. 41 Section 2. This act shall take effect July 1, 2021.